Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers

PURPOSE: Tocilizumab (TCZ) through intravenous infusion has been shown to effectively treat active thyroid eye disease (TED) refractory to systemic steroids. TCZ is also available as a self-administered subcutaneous injection, but data demonstrating the efficacy of this formulation are limited. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Shanlee M., Pirakitikulr, Nathan, Lee, Bradford W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988969/
https://www.ncbi.nlm.nih.gov/pubmed/35399969
http://dx.doi.org/10.4103/tjo.tjo_59_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988969/
https://www.ncbi.nlm.nih.gov/pubmed/35399969
http://dx.doi.org/10.4103/tjo.tjo_59_21

Ejemplares similares